Background: There are currently no approved targeted therapies for non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (ins20), a subgroup of EGFR mutations that are generally refractory to first/second generation EGFR inhibitors. We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20.
Introduction
EGFR exon 20 insertions (ins20) comprise a unique subset (4%-10%) of EGFR mutations in non-small-cell lung cancer (NSCLC) [1, 2] . In contrast to the more common EGFR activating mutations such as exon 19 deletions and L858R, cancers harboring EGFR ins20 are generally refractory to first-and second-generation EGFR tyrosine kinase inhibitors (TKIs) including erlotinib, afatinib and gefitinib. Among patients with EGFR ins20, the median progression-free survival (mPFS) to these drugs is only 3 months [1, 3, 4] , compared with 9-13 months for the more common EGFR mutations [5] [6] [7] . Additionally, the diversity of these mutations, which have a range of sequences and lengths, may contribute to the difficulty in effectively targeting this subgroup [8] [9] [10] . Currently, there are no approved targeted therapies available for patients with EGFR ins20, and novel treatment approaches are needed.
Heat shock protein 90 (hsp90) is a molecular chaperone responsible for the post-translational folding and stability of client proteins. Hsp90 inhibition leads to the degradation of client proteins by the ubiquitin proteasome pathway [11] . Hsp90 clients include EGFR and many other key cancer oncogenes [11] . Thus, hsp90 inhibition has been studied as a potential therapeutic strategy in NSCLC and other malignancies.
Luminespib (AUY922) is a potent, ATP-competitive, non-geldanamycin hsp90 inhibitor which is administered intravenously (i.v.) weekly [12] . Luminespib's activity in lung cancer has previously been investigated in a phase II study across several molecularly-defined NSCLC subtypes [13] . In that study, luminespib had an objective response rate (ORR) of 9.7%-17.1% among EGFR-mutant NSCLCs. Notably, one patient with an EGFR ins20 responded to luminespib. This response, along with preclinical data supporting the use of hsp90 inhibitors in NSCLC cells with diverse exon 20 insertions [14] , prompted further evaluation of the drug's activity specifically in this lung cancer subtype. Here, we present the final results of an open-label, phase II study of luminespib in patients with advanced NSCLC harboring EGFR ins20.
Methods

Study design
NCT01854034 was a phase II, single arm, open label, investigatorinitiated trial of luminespib among patients with EGFR ins20-positive NSCLC. The study was conducted at three participating hospitals in Boston, MA, USA between August 2013 and February 2017. The development of luminespib was discontinued during the conduct of the trial and the study was stopped prematurely on 28 February 2017 when all available drug supply expired. The study had completed full planned enrollment of 29 patients, but 3 patients remained on treatment when the study ended.
Patients with advanced (stage IIIB/IV) NSCLC with an EGFR exon 20 insertion identified by a local, Clinical Laboratory Improvement Amendments (CLIA)-certified assay were included. Central confirmation of EGFR exon 20 insertion was not mandated on the study, but confirmatory molecular testing was carried out at the treating institution in some cases. All patients were required to have received at least one prior line of systemic therapy; there was no limit on the maximum number of therapies received. Patients with stable, asymptomatic brain metastases were included. All patients were treated with a standard starting dose of luminespib of 70 mg/m 2 administered i.v. weekly. Dose reductions and interruptions were allowed as needed to manage drug-related toxicities. Response assessment was carried out centrally using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [15] . Treatment beyond RECISTdefined progression was allowed for patients who continued to benefit clinically from treatment at the discretion of the treating investigator.
Treatment was administered weekly in continuous 21-day cycles. Patients were evaluated for toxicity on a weekly basis. Standard ophthalmologic assessments were carried out at baseline, at the time when visual symptoms were first reported or at the beginning of the third cycle of treatment, and at study discontinuation. Electrocardiograms were carried out at baseline, following infusion, and 24 and 48 h post-treatment on day 1 of cycle 1, then pre-and post-treatment for all subsequent infusions. Restaging scans were carried out every 6 weeks.
Statistical design
The primary objective of the study was to evaluate the ORR of luminespib among NSCLC patients with EGFR ins20. The pre-determined target rate of effectiveness was defined as the rate of partial response (PR) plus stable disease (SD) lasting 3 months of 20% (each measured from the start of treatment), whereas 5% or less was considered the threshold for ineffectiveness of luminespib in this population. The study design had 80% power to detect this difference, with a one-sided a-level of 0.05. The total planned sample was size was 29 patients in a Simon two-stage design. Ten patients were enrolled in the first stage, with a plan to continue enrollment of an additional 19 patients in the second stage if at least one PR or SD lasting >3 months was observed in the first stage. All patients who received at least one dose of luminespib are included in the safety analyses. All patients who underwent restaging exams are included in the efficacy analyses.
Results
Patient characteristics
A total of 29 patients were enrolled at the three participating study sites between August 2013 and October 2016 (Table 1) . They included 18 women and 11 men and had a median age 60 years (range 31-79). The median number of prior treatment lines was 1 (range 1-5). Six patients had received prior treatment with an FDA-approved EGFR TKI (erlotinib-5, afatinib-1); there were no clinical responses to EGFR TKI monotherapy. None of the patients had received an experimental EGFR TKI targeting EGFR ins20 (specifically, poziotinib or TAK-788) before treatment with luminespib. The breakdown of specific EGFR ins20 subtypes is shown in Table 2 . In four patients, the specific EGFR ins20 mutation was not known. In two of these four cases ( Table 2 , study ID 12 and 22), local testing did not specify the exact mutation and tissue was not available for confirmatory testing. In two additional cases (study ID 6 and 4), confirmatory testing at the treating institution did not identify an EGFR ins20 despite a positive result on local testing, including one case (study ID 6) in which an EML4-ALK rearrangement was instead identified.
Efficacy
We observed one PR and three patients with SD lasting more than 3 months among the first 10 patients, meeting pre-specified criteria to proceed to full planned enrollment. In the overall intent-to-treat population, five patients achieved confirmed PR, for an ORR of 17% (Figure 1 ). Six additional patients achieved SD lasting >3 months, yielding a rate of effectiveness by the predefined criteria of 38%, exceeding the target threshold of 20%. Nine patients (31%) had progressive disease (PD) as their best response. As noted above, two patients who were reported to have EGFR exon 20 insertions on local testing later tested negative by confirmatory testing at the treating institution (including one patient whose tumor was found to be ALK-positive); these two patients each had SD lasting <3 months on luminespib.
Excluding these two patients from the analysis, the ORR is 19% and the target rate of effectiveness is 41% among the remaining 27 patients. The estimated mPFS of the overall study population was 2.8 months (95% CI 1.3-5.6 months; Figure 2 ). The median overall survival (mOS) from study entry was 9.9 months (95% CI 4.5-19.2). When excluding the 2 patients who tested negative for EGFR exon 20 insertions, the mPFS of the remaining 27 patients is 3.3 months (95% CI 1.3-5.6) and mOS is 12.8 months (95% CI 4.5-19.2). Eight out of the twenty-nine patients received treatment beyond RECIST PD lasting more than one postprogression cycle (Figure 3 ). Ten out of the twenty-nine patients remained on treatment for more than 6 months, including 6 patients whose best response was SD and 4 patients with a PR. Three patients were receiving treatment (one with ongoing PR, one with ongoing SD and one with PD being treated beyond progression after receiving radiation to progressive CNS metastases) at the time of study closure due to lack of drug supply. Among these patients, two patients immediately transitioned to another systemic therapy, while the third (who had a sustained PR at the time of study closure) had a treatment holiday of 6 months before progression.
Finally, we analyzed luminespib response by EGFR ins20 subtype. More than 20 unique insertions have been described in EGFR exon 20 [1, 2] . We saw no correlation between ins20 subtype and response to luminespib (Table 2 ). Responses were seen among patients with the following mutations: D770_N771insSVD, D770_P772dup, N771insGF, P772_H773 dupPH and P773dup.
Safety
All 29 patients were evaluable for toxicity. Treatment-related adverse events (AEs) observed in the study are summarized in Table 3 . The most common treatment-related AEs included diarrhea (n ¼ 24, 83% including all grades), ocular toxicity (n ¼ 22, 76%), fatigue (n ¼ 13, 45%) and hypertension (n ¼ 12, 41%). Grade 3 treatment-related AEs included ocular toxicity (n ¼ 1, 3%), hypertension (n ¼ 3, 10%) and hypophosphatemia (n ¼ 2, 7%). All grade 3 toxicities were reversible. Six out of the twentynine (21%) patients required dose reduction of luminespib due to toxicities, and 17/29 (59%) patients required treatment delays or interruptions to manage treatment-related AEs. We found that both strategies were effective in managing toxicities, and only two patients ultimately discontinued treatment due to persistent visual toxicities.
Discussion
This phase II single-arm, open label study evaluated the activity of the hsp90 inhibitor luminespib among NSCLCs with EGFR ins20. The study met its primary end point with a disease control rate of 38%, suggesting that luminespib may be an effective therapy in this molecularly defined NSCLC subtype. The overall ORR of 17% and mPFS of 2.8 months are modest, but comparable to other approved second-line NSCLC therapies including docetaxel [16] [17] [18] . The response was higher (19%) when excluding the two patients who were not confirmed to have EGFR exon 20 insertions on repeat testing. More than one-third of the study population remained on treatment for 6 months or more, including four patients who received luminespib for more than 1 year, highlighting both the potential durable benefit and tolerability of luminespib.
The safety profile of luminespib was consistent with previous reports. Treatment-related diarrhea, ocular toxicity and fatigue were common, but generally mild. Serious toxicities were rare and reversible. The ocular toxicity associated with luminespib (typically described by patients as difficulty seeing in dark conditions, general dimming of the visual fields or other visual disturbances) is common and well-described [19] . These symptoms appear to be related to direct damage of the retinal pigment epithelial cells and adjacent photoreceptors by hsp90 inhibitors. It has been reported that hydrophilic agents, including luminespib, result in more sustained retinal exposure and slower exposure, leading to more pronounced visual symptoms than hydrophobic compounds [20] . We found these visual symptoms to be universally reversible when luminespib was held, and generally well-managed with dose interruptions. If further studies with luminespib are planned, an intermittent dosing strategy (e.g. a 3 weeks on, 1 week off schedule) could be considered to mitigate treatment-related toxicities including visual symptoms.
Although there are currently no FDA-approved targeted therapies for lung cancers harboring EGFR ins20, multiple TKIs that were specifically designed to target both EGFR ins20 and ERBB2 ins20 using structural models of these mutants [2] are now being tested in clinical trials. The oral EGFR TKI poziotinib has demonstrated preliminary activity (ORR 7/11 patients, 64%) in an ongoing phase II study (NCT03066206) [21] , while TAK-788 has also shown responses among patients with EGFR ins20 in an ongoing phase I trial (NCT02716116) [22] . A phase II study of osimertinib among EGFR ins20 patients is also recruiting (NCT03191149). We are optimistic that one or more of these new drugs will lead to both activity and a tolerable toxicity profile, with eventual regulatory approval in this underserved patient population. Nevertheless, we see a role for further study of luminespib or other hsp90 inhibitors, which act by a different mechanism than TKIs and could potentially benefit patients who do not respond to or become resistant to other novel therapies. The development of luminespib was halted during the conduct of our study and the trial had to be stopped prematurely when all available drug supply expired in February 2017. Three patients were still receiving treatment at this point, including one patient with a sustained PR and another with a prolonged period of SD. A third patient had disease progression in the CNS treated with radiation, but had was continuing to benefit clinically from postprogression therapy. Unfortunately, we were unable to identify a mechanism to extend the expiration of the drug and allow these patients to continue treatment. This highlights a major limitation of our current system of drug development, and the need for innovative strategies to provide ongoing treatment to responding patients when drug supplies are limited.
In summary, this study met its primary end point and suggests that luminespib may be an active therapy for advanced NSCLC patients with EGFR ins20. Luminespib is generally well-tolerated. Low-grade ocular toxicity, fatigue and diarrhea were common, but could typically managed with dose interruptions. Further study of luminespib or other hsp90 inhibitors in this population is warranted.
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